Lewis Katz School of Medicine at Temple University's Department of Emergency Medicine is participating in a nationwide study to pinpoint the best treatment for community-acquired methicillin-resistant Staphylococcus aureus (MRSA), an increasingly common antibiotic-resistant infection.
Leading the research effort at Lewis Katz School of Medicine is David Karras, MD, Professor and Associate Chair of the Department of Emergency Medicine. The objective of this trial is to determine the best outpatient therapy for otherwise healthy people who have MRSA. There is no information on the optimal treatment for this latest strain, which is resistant to many of the traditional oral antibiotics.
As one of four subcontractors nationwide and the only site in Philadelphia, Lewis Katz School of Medicine is the recipient of $1.8 million in funding from the Olive View-UCLA Education and Research Institute, the lead investigator for STOP-MRSA, a $9 million, five-year, five-center trial funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
STOP-MRSA is evaluating various treatments for patients with skin and soft tissue infections caused by community-acquired-MRSA. Standard treatments for MRSA have included a variety of antibiotics and the draining of abscesses, but experts are not yet certain about the most effective treatment.
Residents and students are invited to participate in on-going studies and to initiate related investigational studies under the guidance of Dr. David Karras.